ArticleJournal of virology2025
Broad-spectrum inhibition of influenza A virus replication by blocking the nuclear export of viral ribonucleoprotein complexes.
Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Influenza A virus (IAV) remains a major threat to global health. The emergence of IAV strains resistant to commonly used anti-influenza medicines has made the need for novel broad-spectrum antiviral agents more urgent. The IAV nucleoprotein (NP) is one of the most conserved viral proteins encoded by IAV and is essential for multiple processes in the lifecycle of IAVs. In this study, we screened a high-affinity nanobody, Nb7, which specifically recognizes NP from different subtypes of IAV and broadly inhibits the replication of various IAVs. Mechanistically, Nb7 blocked the nuclear export of viral ribonucleoprotein (vRNP) complexes and the subsequent assembly of progeny virions by specifically binding the nuclear export sequence 1 (NES1) region of the NP. The conserved Q42/E46/K48 residues within the NES1 region of NP were identified as the key sites for the binding of Nb7 and were synergistically responsible for the nuclear export of vRNP. In addition, Nb7 fused with a trans-activating transduction peptide efficiently inhibited the replication of IAV IMPORTANCE: Influenza A viruses (IAVs) cause seasonal epidemics and global pandemics, resulting in hundreds of thousands of deaths annually. The identification of conserved epitopes and the development of effective prevention and treatment strategies are crucial for addressing these challenges. The nucleoprotein (NP) protein of IAV is a key component of the viral ribonucleoprotein (vRNP) complex and is highly conserved in various subtypes. Therefore, the development of vaccines or drugs that target conserved viral proteins such as the NP is promising. We screened Nb7, which specifically recognizes NP and broadly inhibits IAV replication through blocking the nuclear export of vRNP. More importantly, the trans-activating transduction peptide-fused Nb7 has promising effects for the prevention and treatment of IAV infection. Our present study provides novel insight for the further development of broad-spectrum vaccines and anti-influenza drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.